Company Overview: Isoray

Industry News

8 Feb

IsoRay Announces Second Quarter Fiscal 2017 Financial Results

RICHLAND, Wash., Feb. 8, 2017 /PRNewswire/ –­­ IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced financial results for the second quarter of fiscal 2017, ended December...

Read more

7 Feb

MicroCap Review Magazine Winter/Spring 2017 Issue Now Available

LOS ANGELES, Feb. 7, 2017 /PRNewswire/ — SNN Incorporated, a global multimedia financial news and publishing company focused on the MicroCap stock market, and publisher of the MicroCap Review Magazine, is pleased to announce the release of the MicroCap Review Magazine Winter/Spring 2017 issue online and in print. The Winter/Spring...

Read more

21 Dec

IsoRay, Inc. Announces the Launch of a Pilot Study Using Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Resectable High Risk Recurrent Head and Neck Cancer by Case Comprehensive Cancer Center

RICHLAND, Wash., Dec. 21, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of a pilot study investigating the role of...

Read more

30 Nov

IsoRay to Present at 9th Annual LD Micro Investor Conference

RICHLAND, Wash., Nov. 30, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that Tom LaVoy, Chairman and CEO, and Brien Ragle,...

Read more

29 Nov

IsoRay Announces “Cesium-131 Brachytherapy for Salvage of Recurrent High Grade Glioma” Poster Presentation at 21st Annual Scientific Meeting of Society for Neuro-Oncology

RICHLAND, Wash., Nov. 29, 2016 /PRNewswire/ –­­ IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in Cesium-131 seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced a poster presentation at the 21st Annual Meeting...

Read more

27 Sep

IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation

RICHLAND, Wash., Sept. 27, 2016 ­/PRNewswire/ — IsoRay, Inc. (“IsoRay”) (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that on September 23, 2016, it entered into...

Read more

6 Jul

Women’s Cancer and Cesium-131 Treatments: Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy

RICHLAND, Wash., July 6, 2016 /PRNewswire/ — IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced Jonathan Feddock M.D., Assistant Professor of Radiation Medicine, University of Kentucky College...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address